Capricor Therapeutics (CAPR) Liabilities and Shareholders Equity (2010 - 2026)

Capricor Therapeutics' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $326.3 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 112.19% year-over-year to $326.3 million; the TTM figure through Mar 2026 stood at $942.2 million (up 106.87% YoY), while the FY2025 annual figure was $355.9 million, up 108.79% from the prior year.
• Liabilities and Shareholders Equity was $326.3 million for Q1 2026 at Capricor Therapeutics, down from $355.9 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $355.9 million in Q4 2025 to a low of $37.2 million in Q3 2023.
• Historically, Liabilities and Shareholders Equity has averaged $110.0 million across 5 years, with a median of $58.7 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity sank 31.11% in 2023, then soared 248.95% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $50.1 million in 2022, then rose by 17.25% to $58.7 million in 2023, then soared by 190.26% to $170.5 million in 2024, then jumped by 108.79% to $355.9 million in 2025, then fell by 8.33% to $326.3 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $326.3 million (Q1 2026), $355.9 million (Q4 2025), and $126.4 million (Q3 2025), per Business Quant data.